575 related articles for article (PubMed ID: 17694444)
1. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
2. Bi-specific antibody therapy for the treatment of cancer.
Withoff S; Helfrich W; de Leij LF; Molema G
Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
[TBL] [Abstract][Full Text] [Related]
3. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives of bispecific antibody-based immunotherapy.
Talac R; Nelson H
J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
[TBL] [Abstract][Full Text] [Related]
5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
Kipriyanov SM; Le Gall F
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies for cancer therapy.
Chames P; Baty D
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
9. Antibody engineering: facing new challenges in cancer therapy.
Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
[TBL] [Abstract][Full Text] [Related]
10. [Cancer therapy by using bispecific antibody].
Azuma A; Niitani H; Okumura K
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
[TBL] [Abstract][Full Text] [Related]
11. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
12. A revival of bispecific antibodies.
Kufer P; Lutterbüse R; Baeuerle PA
Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
[No Abstract] [Full Text] [Related]
13. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
14. New approaches to antibody therapy.
Weiner LM; Adams GP
Oncogene; 2000 Dec; 19(53):6144-51. PubMed ID: 11156528
[TBL] [Abstract][Full Text] [Related]
15. [Bispecific antibodies: what future?].
Pèlegrin A; Robert B
Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
[TBL] [Abstract][Full Text] [Related]
16. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
MacDonald GC; Glover N
Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies for cancer immunotherapy: Current perspectives.
Müller D; Kontermann RE
BioDrugs; 2010 Apr; 24(2):89-98. PubMed ID: 20199124
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer.
Kershaw MH; Trapani JA; Smyth MJ
Ther Immunol; 1995 Jun; 2(3):173-81. PubMed ID: 8885135
[TBL] [Abstract][Full Text] [Related]
19. Diabodies: molecular engineering and therapeutic applications.
Wu C
Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
[TBL] [Abstract][Full Text] [Related]
20. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
